REVIEW

Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies

Jiawen Zhang[1,2]*, Sihui Yu[3]*, Qiao Peng[1], Ping Wang[1], Lan Fang[1]

[1]Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China; [2]Reproductive Medicine Center, Department of Obstetrics and Gynecology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China; [3]Department of Obstetrics and Gynecology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

ABSTRACT   The intricate interplay between the human immune system and cancer development underscores the central role of immunotherapy in cancer treatment. Within this landscape, the innate immune system, a critical sentinel protecting against tumor incursion, is a key player. The cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) pathway has been found to be a linchpin of innate immunity: activation of this signaling pathway orchestrates the production of type I interferon (IFN-α/β), thus fostering the maturation, differentiation, and mobilization of immune effectors in the tumor microenvironment. Furthermore, STING activation facilitates the release and presentation of tumor antigens, and therefore is an attractive target for cancer immunotherapy. Current strategies to activate the STING pathway, including use of pharmacological agonists, have made substantial advancements, particularly when combined with immune checkpoint inhibitors. These approaches have shown promise in preclinical and clinical settings, by enhancing patient survival rates. This review describes the evolving understanding of the cGAS-STING pathway's involvement in tumor biology and therapy. Moreover, this review explores classical and non-classical STING agonists, providing insights into their mechanisms of action and potential for optimizing immunotherapy strategies. Despite challenges and complexities, the cGAS-STING pathway, a promising avenue for enhancing cancer treatment efficacy, has the potential to revolutionize patient outcomes.

KEYWORDS   cGAS-STING pathway; type I interferon; cyclic dinucleotide; STING agonist; cancer immunotherapy

Introduction

The human immune system plays critical roles in tumor development, progression, and metastasis, and is central to cancer therapy. Tumor immune surveillance relies predominantly on the innate immune system, a fundamental mechanism safeguarding the body against tumor intrusion by recognizing, regulating, and eliminating malignant cells. The efficacy of tumor antigen-specific T cells relies on signals originating

*These authors contributed equally to this work.
Correspondence to: Ping Wang and Lan Fang
E-mail: wangp@tongji.edu.cn and lanfang@tongji.edu.cn
ORCID ID: https://orcid.org/0000-0002-9922-5407
and https://orcid.org/0000-0001-8477-0528

from the innate immune system, which greatly influence T cells' ability to combat tumor cells[1].

In innate immunity, pattern recognition receptors (PRRs) detect molecules associated with infections, cellular stress, and tissue damage. Throughout tumor initiation and progression, cancer cells generate a plethora of damage-associated molecular patterns; these molecules interact with PRRs and subsequently trigger innate immune responses[2]. In innate immunity, the cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING) pathway plays an instrumental role. This pathway is a dedicated mechanism for sensing and signaling in response to specific DNA stimuli[3]. Substantial evidence indicates that cGAS detects double-stranded DNA (dsDNA) originating from deceased cancer cells, mitochondria, and other sources. This recognition event activates the STING signaling cascade and culminates in the production of type I interferon (IFN-α/β). IFN-α/β in turn orchestrate the maturation, differentiation, and mobilization of dendritic cells (DCs), macrophages, natural killer (NK) cells, effector T

cells, and other immune effectors. Furthermore, the STING signaling pathway elicits the release of tumor antigens, thereby facilitating their cross-presentation by antigen-presenting cells[4,5]. Given its critical role in reshaping the tumor microenvironment (TME), STING has emerged as an attractive target for cancer immunotherapy.

Intervention strategies aimed at activating the cGAS-STING pathway, such as the use of pharmacological agonists, have achieved substantial advancements in both preclinical and clinical research settings. Activation of the cGAS-STING pathway has shown favorable tumor regression effects in clinical models, by evoking systemic anti-tumor responses, particularly when combined with immune checkpoint inhibitors (ICIs). These combination therapies have achieved remarkable improvements in survival rates in phase I clinical trials[6,7]. Consequently, STING pathway activation is considered a means of increasing tumor immunotherapy efficacy through mobilizing both innate and adaptive immune mechanisms.

In this review, we aim to comprehensively describe cutting-edge developments in exploiting the cGAS-STING pathway in tumor biology and therapy. We discuss the current research landscape of classical and non-classical STING agonists used for cGAS-STING pathway activation. These investigations have not only increased understanding of the mechanisms underpinning the cGAS-STING pathway in tumor immunity but also have provided a critical theoretical framework for developing more efficacious immunotherapy strategies. These efforts have the potential to revolutionize the efficacy of cancer treatments and enhance patient survival rates.

cGAS-STING signaling pathway

cGAS, a member of the nucleotidyl transferase family, contains unstructured N-terminal and C-terminal catalytic domains[8]. This enzyme is essential in the surveillance of diverse sources of dsDNA. After binding dsDNA, cGAS dimerizes, forming a cGAS-dsDNA complex comprising 2 cGAS molecules and 2 dsDNA molecules[9]. Crystallographic analysis has demonstrated that in the dsDNA-cGAS interaction, longer DNA strands have greater efficacy than shorter DNA strands in facilitating cGAS liquid-liquid phase separation and enzymatic activity, thus enabling cGAS to catalyze the synthesis of 2′3′-cGAMP from adenosine triphosphate (ATP) and guanosine triphosphate (GTP)[10]. Recent investigations have indicated that, although RNA does not activate cGAS *in vitro*, it potentiates cGAS phase separation. Particularly when dsDNA

concentrations are limited, RNA fosters cGAS-containing phase separation and consequently increases cGAS activity[11]. In contrast to other closely related cyclic dinucleotides (CDNs), the product of cGAS, 2′3′-cGAMP, is as a distinctive dinucleotide featuring a phosphodiester bond between the 2′-hydroxyl of GMP and the 5′-phosphate of AMP, as well as another phosphodiester bond between the 3′-hydroxyl of AMP and the 5′-phosphate of GMP. These structural attributes enhance affinity for the human STING receptor[8].

STING, encoded by the transmembrane protein 173 (TMEM173) gene, is a transmembrane protein with an N-terminal domain and a C-terminal domain, each bearing 4 transmembrane structures, and existing in a homodimeric configuration[12]. In its quiescent state, STING resides in the endoplasmic reticulum (ER) membrane and the outer mitochondrial membrane, and its C-terminus freely extends into the cytoplasm. After binding cGAMP, STING undergoes substantial conformational changes, which trigger its translocation from the ER to the ER-Golgi intermediate compartment, in a process crucial for signal transduction[13]. Subsequently, STING recruits TANK-binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3). TBK1 phosphorylates serine residue S366 in the C-terminus of STING, thereby activating IRF3 and prompting its translocation to the nucleus. IRF3 subsequently facilitates the transcription of IFN-α/β and immune-stimulating genes[14]. In addition to phosphorylation, palmitoylation of STING at C88/C91 is indispensable for assembling the signal complex, through facilitating STING aggregation in the Golgi apparatus[15]. Concurrently, STING activates IκB kinase (IKK) and consequently governs the production of NF-κB-mediated inflammatory factors[16]. A recent study has proposed that STING protein also functions as a hydrogen ion channel facilitating Golgi hydrogen ion efflux, thereby promoting non-classical autophagy and NLRP3 inflammasome activation[17]. Moreover, STING interacts with hexokinase 2 (HK2), a rate-limiting enzyme in glycolysis, and subsequently restrains the mitochondrial localization of HK2, thus inhibiting its activity and suppressing glycolysis (**Figure 1**)[18].

Additionally, in cGAS-STING signal transduction, the activity and stability of cGAS and STING are regulated by various post-translational modification mechanisms such as ubiquitination, phosphorylation, SUMOylation, and neddylation[19-23]. An in-depth exploration of the structural and biological facets of the cGAS-STING signaling pathway can be found in recent comprehensive reviews[5,9,24].

Figure 1　The cGAS-STING signaling pathway. Double-stranded DNA (dsDNA) derived from the nuclear DNA damage response (DDR), mitochondria, and micronuclear DNA activates cyclic GMP-AMP synthase (cGAS) and drives the synthesis of 2′,3′-cyclic GMP-AMP (cGAMP). After binding cGAMP, stimulator of interferon genes (STING) is translocated from endoplasmic reticulum (ER) to the Golgi and ER-Golgi intermediate compartment (ERGIC). Subsequently, STING recruits and activates TANK-binding kinase 1 (TBK1), which in turn phosphorylates interferon regulatory factor 3 (IRF3) and nuclear factor κB (NF-κB). IRF3 and NF-κB then translocate into the nucleus, where they facilitate the transcription of type I-interferon and immune-stimulating genes. In the ER, STING interacts with protein kinase R (PKR)-like ER kinase (PERK), thus leading to its activation. STING also functions as a hydrogen ion channel facilitating Golgi hydrogen ion efflux, thereby promoting non-classical autophagy and NLRP3 inflammasome activation. Moreover, nuclear cGAS inhibits DNA homologous recombination repair, whereas UHRF1 regulates the chromosomal untethering of cGAS. mtDNA, mitochondrial DNA; HK2, hexokinase 2; IL6, interleukin-6; TNF, tumor necrosis factor; ATG5, autophagy-related 5.

The cGAS-STING pathway in cancer biology

Mechanisms of cGAS-STING pathway activation in cancer cells

A hallmark of cancer is the DNA damage response (DDR), which encompasses the recognition, signaling, and repair of DNA damage[25]. Emerging evidence has shown that endogenous DDR defects in cancer cells activate the cGAS-STING pathway. These mechanisms primarily involve the overproduction of abnormal DNA fragments in the nucleus, and the presence of micronuclei DNA or chromatin fragments associated with senescence in the cytoplasm[26].

Extensive DNA damage, whether intrinsic or induced by treatments such as radiation or chemotherapy, produce dsDNA fragments that activate the cGAS-STING pathway[27]. Repair factors, including mutL homolog 1 (MLH1) and the excision repair cross-complementation group 1 (ERCC1), replication stress-associated SAM and HD domain-containing protein 1 (SAMHD1), and the ataxia-telangiectasia mutated

(ATM)-checkpoint kinase, are closely associated with cGAS-STING activation[28-30]. Moreover, cancer cells tend to accumulate other types of abnormal DNA, such as extrachromosomal circular DNA elements and extrachromosomal telomere repeat DNA, which evoke robust IFN-α/β responses, and subsequently activate immune responses in macrophages and DCs[31].

Mislocalized DNA, accompanied by chromatin fragments associated with senescence in the cytoplasm, is encapsulated within micronuclei in cells. In pre-cancerous or cancerous cells, structural membrane anomalies render micronuclei and senescence-associated cytoplasmic chromatin fragments susceptible to rupture and release of highly immunostimulatory dsDNA fragments that bind and activate cGAS[32]. Notably, particularly in the case of radiation therapy, DNA damage-induced micronucleus formation contributes to the expression of pro-inflammatory genes and cytokines, thereby leading to innate immune activation in mouse mammary carcinoma cells[33]. Diverse mechanisms have been identified in the autoactivation of cGAS that has encountered DNA in micronuclei in various cancer scenarios. For instance, mutations in the RecQ-like helicase BLM or defects in RNase H2 can lead to formation of micronuclei and cGAS-dependent IFN-α/β responses; consequently, patients with Bloom syndrome are susceptible to all types of cancer[34]. Liu et al.[35] have revealed that DNA damage can lead to translocation of cGAS from the cytoplasm to the nucleus in a manner dependent on importin-α, whereas phosphorylation of cGAS at residue Y215 promotes its cytoplasmic retention. Inside the nucleus, cGAS is recruited to sites of dsDNA breaks, where it interacts with poly(ADP-ribose) and inhibits the formation of the poly-adenosine diphosphate ribose polymerase 1 (PARP1)-Timeless complex, thereby impeding homologous recombination. PARP inhibitors (PARPi) enhance cancer cell immunogenicity *via* the cGAS-STING signaling pathway in the context of ERCC1 or the breast cancer susceptibility genes (BRCA) defects. Several studies have indicated that changes in chromatin states induced by chemoradiotherapy significantly influence cGAS recruitment, whereas the inner nuclear membrane-anchored exonuclease three prime repair exonuclease 1 (TREX1) degrades DNA and mitigates the effects of IFN-α/β[36,37]. Recently, our group has shown that multiple cancer cells induce chromatin untethering and activity inhibition of cGAS through competitive uptake of methionine. Mechanically, cGAS undergoes methylation modifications at multiple sites, among which K362 methylation is dependent on methionine and S-adenosylmethionine. The chromatin binding protein ubiquitin-like, containing PHD and RING finger domains 1 (UHRF1) recruits methylated cGAS and promotes

its chromosome binding, whereas short-term methionine restriction or targeted interventions with methyltransferase suppressor of variegation 3–9 homolog 1 (SUV39H1) decrease cGAS methylation, and consequently promote its chromosome dissociation and entry into the cytoplasm. Subsequently, cytoplasmic cGAS is again activated by dsDNA, thus enhancing the anti-tumor immune phenotype of radiation therapy and ICIs[38].

Beyond the aforementioned abnormal DNA sources, other potential contributors may activate the cGAS-STING pathway in cancer cells. Tumors have been suggested to indirectly evoke cGAS-STING activation through endogenous retrotransposons, thereby leading to genome integrity impairment, accumulation of DNA damage products, or the formation of micronuclei[39]. For example, the upregulation of L1 retrotransposons is correlated with late-stage senescence and enhances cGAS-STING-dependent IFN-α/β responses—a process exacerbated by diminished TREX1 activity[40]. Additionally, cytosolic DNA released from perturbed mitochondria elicits cGAS-STING activity[41].

In summary, abnormal DNA, although generally associated with promoting cell malignancy and tumor development, concurrently triggers innate immunity in cells in a cGAS-STING-dependent manner. Nevertheless, further investigation is necessary to gain a comprehensive understanding of the precise mechanisms governing these processes.

cGAS-STING facilitates crosstalk between cancer cells and the TME

In cancer, the cGAS-STING pathway has multifaceted influences on tumor immunogenicity, and fosters interactions between cancer cells and various components of the TME. Among its critical anti-tumor effects, the cGAS-STING pathway elicits a potent IFN-α/β response, which is indispensable in activating immune cells in the TME, including DCs, T cells, and NK cells (**Figure 2**).

Activation of cGAS-STING promotes cancer antigen release and presentation

Under conditions of genomic instability, radiotherapy, or chemotherapy, dying cancer cells release cancer antigens, which trigger anti-tumor immune responses. DCs, as critical antigen-presenting cells in the immune system, are responsible for capturing, processing, and presenting antigens, and subsequently initiating T cell-mediated immune responses[42]. Tumor-derived DNA or cGAMP is internalized and processed by DCs that have infiltrated tumors; subsequently the cGAS-STING

Figure 2   The cGAS-STING pathway facilitates crosstalk between cancer cells and the tumor microenvironment (TME). The activation of cGAS-STING promotes the release and presentation of cancer antigens, T cell migration and infiltration, and T cell recognition and cytotoxicity. The cGAS-STING pathway also regulates tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), natural killer (NK) cells, B cells, and cancer-associated fibroblasts (CAFs).

pathway is activated and the production of IFN-α/β is induced. This process drives DC differentiation and maturation, and concurrently enhances major histocompatibility complex class I (MHC-I) expression and facilitates DC-mediated cytotoxic T lymphocyte (CTL) anti-tumor responses[43]. Furthermore, the cGAS-STING pathway amplifies the expression of co-stimulatory molecules (e.g., CD40, CD80, and CD86) on DCs while simultaneously decreasing the expression of inhibitory molecules, such as programmed death-ligand 1 (PD-L1)[44]. Mn^{2+} has been found to augment the maturation of both DCs and macrophages, facilitate the presentation of tumor-specific antigens, promote the differentiation and activation of CD8$^+$ T cells and NK cells, and intensify the presence of memory CD8$^+$ T lymphocytes[45]. In ultraviolet (UV)-irradiated ovalbumin (OVA)-expressing EG7 thymoma cells, IFN-α/β sustains the intracellular presence of antigens in CD8α^+ DCs. These DCs engulf apoptotic EG7 cells, thereby enhancing the cross-presentation of OVA antigens. The deletion of mitochondrial transcription factor A in DCs leads to mitochondrial dysfunction and leakage of mitochondrial DNA (mtDNA) into the cytoplasm, and

subsequently activates the cGAS-STING pathway in DCs. This enhanced antigen presentation effectively reverses the immunosuppressive TME[46].

Activation of cGAS-STING promotes T cell migration and infiltration

In the immune system's recognition and elimination of cancer cells, T cells must initially mobilize and infiltrate tumor tissue. Under the induction of STING signaling, various chemokines [e.g., C-X-C motif chemokine ligand 9 (CXCL9), CXCL10, and C-C motif chemokine ligand 5 (CCL5)] play critical roles in stimulating the migration and infiltration of CTLs[47]. Administration of STING agonists induces the generation of IFN-α/β signals in DCs, thereby stimulating the secretion of chemokines such as CXCL9 and CXCL10, which further promote CTL migration into tumor tissue[48]. Immunotherapy using c-di-GMP activates IFN-α/β signal transduction in CD11b$^+$ cells and facilitates the infiltration of CD8$^+$ T cells into glioblastoma[49]. In mouse models, treatment with cGAMP results in the accumulation of a CD45$^+$CD11b^{mid}Ly6C$^+$

macrophage subpopulations in the TME. These macrophages express numerous chemokines that recruit T cells, thereby modulating the infiltration of CD8[+] T cells and promoting anti-tumor immunity[50]. Moreover, Bruand et al.[51] have revealed that the elimination of endogenous STING in tumors decreases neoangiogenesis, augments CD8[+] T cell infiltration, and reverses resistance to dual immune checkpoint blockade therapy. Ariadne RBR E3 ubiquitin protein ligase 1 (Arih1) mediates the ubiquitination and degradation of DNA PKcs, and consequently triggers STING pathway activation, promotes the infiltration of cytotoxic T cells, inhibits tumor growth, and renders tumors sensitive to PD-L1 blockade[52]. The nuclear receptor Rev-erb alpha (NR1D1) fosters the accumulation of cytoplasmic DNA fragments induced by DNA damage, and subsequently activates the cGAS-STING signaling pathway. This enhancement results in increased production of IFN-α/β, and expression of chemokines such as CCL5 and CXCL10, which in turn regulate the infiltration of CD8[+] T cells and NK cells[53]. These findings further underscore the crucial role of the cGAS-STING signaling pathway in promoting T cell migration and infiltration.

Enhancing T cell recognition and cancer cell killing through cGAS-STING activation

T cells play essential roles in the immune response against cancer cells, primarily by recognizing tumor-specific antigens presented on MHC-I molecules *via* their T cell receptors. Multiple studies have demonstrated the importance of STING pathway activation in increasing CTL engagement and eliciting robust anti-tumor responses.

In murine models, treatment of CT26 colorectal cancer or 4T1 breast cancer cells with radiation has been demonstrated to initiate effective STING-dependent CTL responses[43]. Platinum-based chemotherapy has similarly been shown to activate STING and increase expression of MHC-I in cancer cells. This heightened MHC-I expression facilitates the recognition of cancer cells by CTLs, thereby amplifying CTL-mediated anti-tumor effects. In contrast, ionizing radiation upregulates the expression of PD-L1 in liver cancer cells *via* activation of the STING-TBK1-IRF3 immune pathway. This upregulation of PD-L1 dampens CTL activity and ultimately shields cancer cells from immune-mediated clearance. Furthermore, cGAMP treatment has been found to augment the anti-tumor effects of radiation in a hepatocellular carcinoma mouse model, thus bolstering the cytotoxic capabilities of tumor-specific CD8[+] T cells[54]. Huang et al.[55] have recently developed a collaborative nanoplatform promoting the infiltration of CD8[+] T cells

into tumors. This platform restores T cell function by modulating tyrosine metabolism and activating the STING pathway. Moreover, targeting STING for systemic therapy in mice eliminates tumor cell dormancy and metastasis in a T cell and NK cell dependent manner[56]. Interestingly, intrinsic STING in T cells also decreases apoptosis and enhance long-term T cell protective immunity[57]. Collectively, these findings highlight the promise of activating the STING pathway as a potential strategy for inducing potent anti-tumor immune responses.

Regulation of tumor-associated macrophages (TAMs) by cGAS-STING activation

TAMs play a major role in tumorigenesis, and targeting TAM function is a potential therapeutic approach to mitigating tumor metastasis[58]. Notably, studies have illuminated the influence of cGAS-STING activation on TAM behavior. Ohkuri et al.[50] have reported that injection of cGAMP into mouse tumor tissue results in macrophage aggregation, whereas this effect is absent in STING knockout mice. Notably, the anti-tumor effects induced by cGAMP are abrogated after macrophage depletion in mice. Moreover, ATP enhances the transport of extracellular cGAMP to macrophages through the ATP-gated P2X purinoceptor 7 (P2X7) receptor (P2X7R) and subsequently leads to STING activation[59]. Further analysis has revealed that STING-induced tumor-associated migratory macrophages exhibit elevated levels of T cell-recruiting chemokines, such as CXCL10 and CXCL11, which facilitate CD8[+] T cell recruitment to tumor sites. STING activation has been shown to reprogram TAMs into an M1 phenotype, and to transform immunologically "cold" peritoneal tumors into T cell-inflamed tumors in an IFN-α/β-dependent manner[60]. In lung and breast cancers, the STING pathway has been found to be deactivated and positively correlated with macrophage markers. Treatment with vanillic acid has been demonstrated to stimulate the STING/TBK1/IRF3 pathway, thus inducing IFN-α/β production and promoting macrophage polarization toward an M1 phenotype, and enhancing phagocytosis and apoptosis induction[61]. In a model of liver cancer metastasis, STING activation has been found to influence TAM polarization and to promote the nuclear translocation of transcription factor EB *via* interferon-associated GTPase 1. This process affects macrophages' ability to suppress tumor metastasis[62]. Moreover, STING activation assists macrophages in secreting interleukin-18 (IL-18) and interleukin-1β (IL-1β), thereby optimizing NK cell anti-tumor activity through promoting the expression of 4-1BBL in macrophages and 4-1BB in NK cells[63]. Additionally, the

disruption of protein phosphatase 2A catalytic subunit (PP2Ac) in glioblastoma cells enhances dsDNA production and cGAS-IFN-α/β signaling. This process increases MHC-I expression, decreases immunosuppressive TAMs, and sensitizes tumors to immune checkpoint blockade and radiotherapy[64]. Ho et al.[65] have found that, in TAMs, protein PP2A and its specific B regulatory subunit Striatin 4 (STRN4) negatively regulate STING-dependent IFN-α/β production. The diminished accumulation of immunosuppressive macrophages and increased IFN-α/β production in mice lacking macrophage PP2A ultimately decrease tumor progression. Moreover, STING activation has been found to involve the Hippo kinase mammalian sterile 20-like kinase 1/2 (MST1/2), on the basis of observations that STING agonists induce the dissociation of PP2A from MST1/2 in normal macrophages but not in TAMs. In breast cancer cells with BRCA1 mutations, TAMs undergo M2 polarization, which suppresses cancer cell DNA damage induced by PARPi. This suppression decreases dsDNA fragment production and synthetic lethality, and weakens STING-dependent anti-tumor immunity[66]. These findings illuminate the critical role of cGAS-STING-regulated macrophage activity in anti-tumor immunity.

### Activating cGAS-STING to regulate the activity of other immune cells

NK cells have emerged as important components in cancer immunotherapy. Early investigations underscored the importance of STING expression in non-tumor cells for NK cells' ability to selectively target and eliminate cancer cells rather than normal cells[67]. Across various tumor models, STING agonists have shown remarkable potential in enhancing NK cell-mediated anti-tumor responses in a manner independent of CD8+ T cells[68]. These agonists not only promote NK cell migration and cytotoxicity, but also augment the activation of NK cells in combination with CAR-NK cells[69]. Furthermore, they potentiate trastuzumab-mediated NK cell activation and DC maturation *via* STING activation[70], and directly activate NK cells, thereby increasing the sensitivity of pancreatic cancer cells to NK cell-mediated cytotoxicity[71]. Intriguingly, cGAMP induces B cell expression of IL-35 in an IRF3-dependent but IFN-α/β-independent manner. IL-35 secreted by B cells inhibits tumor growth but concurrently suppresses NK cell proliferation, thus tempering NK-driven anti-tumor responses[72]. Recently, Lu et al.[73] have reported that cancer cell derived mtDNA recognition by cGAS triggers the NK cell-intrinsic STING pathway, and consequently promotes antitumor responses and maintains a reservoir of TCF-1+ NK cells.

Myeloid-derived suppressor cells (MDSCs) are a highly heterogeneous population of immature immune cells that support tumor growth and progression by impeding the proliferation and function of effector immune cells. Notably, the cGAS-STING signaling axis influences the recruitment, expansion, and function of MDSCs[74]. c-di-GMP can be used to target MDSCs: even low doses of this compound significantly increase the production of IL-12 by MDSCs[75]. Moreover, STING activation in cancer cells and MDSCs enhances the expression of suppressor of cytokine signaling 1 (SOCS1), which restrains the induction of MDSCs derived from nasopharyngeal carcinoma[76]. The STING pathway, after activation by radiation exposure, leads to the infiltration of MDSCs and, paradoxically, immune suppression, thus ultimately contributing to tumor radioresistance[77]. Additionally, Galectin-1 (Gal1) plays roles in stabilizing STING protein, sustaining NF-κB activation in cancer cells, perpetuating the accumulation of MDSCs in the pre-metastatic niche, and eliciting CXCL2-mediated migration of MDSCs[78].

Cancer-associated fibroblasts (CAFs) are instrumental in shaping responses to cancer treatment and influencing patient outcomes. Activation of the cGAS-STING pathway in tumors plays a major role in defining the characteristics of CAFs, thus resulting in marked upregulation of CAF markers that confer tumor-suppressive properties[79]. Activation of the cGAS-STING pathway further induces the production of interferons and consequently drives overexpression of the urea transporter protein human solute carrier family 14 member 1 (SLC14A1) in a specific subset of CAFs. Notably, targeting STING hinders the formation of SLC14A1-positive CAFs and renders tumor cells more susceptible to chemotherapy[80]. Recently, Dora et al.[81] have reported CAFs expressing STING in the stroma, and suggested that many STING-expressing cells in the stroma might be CAFs in small cell lung cancer tissues. Moreover, STING and IRF3 in stromal fibroblasts can sense genomic stress in cancer cells[82], and targeting IRF3 in CAFs has been found to restore oncolytic herpes simplex virus function[82].

Strategies for harnessing the cGAS-STING pathway in cancer therapy

As described above, the presence of extracellular DNA from various sources, including DNA damage, genetic instability, mitochondria, and exosomes, renders cancer cells susceptible to cGAS-STING pathway activation. cGAS-STING pathway can also be triggered by exogenous stressors, such as radiation

Figure 3 Schematic diagram of harnessing the cGAS-STING pathway in cancer therapy. The accumulation of cytoplasmic and micronuclear DNA fragments induced by radiotherapy, chemotherapy, targeted therapy, and epigenetic therapy activates the cGAS-STING pathway, thus exerting anti-tumor activity. STING agonists independent of cGAS can also be used to directly activate the STING pathway; these agonists include natural cyclic dinucleotide (CDN) and non-CDN agonists. CIRT, carbon ion irradiation; DNMT, DNA methyltransferase; KDM5, lysine-specific demethylase 5; PRMT1, protein arginine methyltransferase 1; EZH2, enhancer of Zeste 2 Polycomb repressive complex 2 subunit; MTA, microtubule-targeting agent; PARP, poly-adenosine diphosphate ribose polymerase; MPS1, monopolar spindle 1; ATM, ataxia telangiectasia-mutated gene; CHK1, checkpoint kinase 1.

and chemotherapy, which induce the accumulation of micronuclei and cytoplasmic DNA fragments[26]. Preclinical investigations have demonstrated that stimulating the cGAS-STING pathway with cytotoxic agents or molecular inhibitors has promise in improving cancer treatment outcomes, particularly in combination therapies with ICIs, thus offering a potential breakthrough in cancer therapy (**Figure 3**).

Strategies based on dsDNA-dependent cGAS-STING pathway activation

Radiotherapy-induced cGAS-STING activation

Radiotherapy, by inducing apoptosis and DNA damage in cancer cells, disrupts DNA structure. Furthermore, radiotherapy evokes extensive DNA damage resulting in cell death

and the release of DNA fragments. Consequently, cGAS-STING pathway activation culminates in the initiation of an immune response[83]. Notably, IFN-α/β has a critical role in reshaping the TME after radiotherapy. As radiation doses escalate, the expression of dsDNA, 2′3′-cGAMP, cGAS, and immune-stimulating genes concomitantly increases in the cytoplasm, alongside elevated levels of IFN-β in the cellular supernatant[84]. Mitochondria are a recognized source of reactive oxygen species, and radiation-induced oxidative stress can lead to the leakage of mtDNA into the cytoplasm and activation of the cGAS-STING pathway[85]. However, that mtDNA is notably not the primary target of radiation, and the probability of DNA double-strand breaks in mtDNA is approximately 0.03% under conditions of 1 Gy of gamma radiation or dense ionizing radiation[86]. After dsDNA breakage, micronuclei form

during mitosis as a consequence of cell cycle progression, preceding the activation of inflammatory signals[87]. Therefore, accumulation and sensing of micronuclei DNA are crucial triggers of the cGAS-STING pathway, which ultimately culminates in IFN-α/β signaling[32]. In summary, radiation-induced micronuclei and dsDNA are indispensable for the sensing of cGAS and activation of STING, thereby facilitating the anti-tumor immune response.

The DNA exonuclease TREX1 is a crucial upstream regulator of radiation-induced cGAS-STING-mediated anti-tumor immunity. Radiation doses exceeding 12–18 Gy induce the expression of TREX1 in various cancer cells, and mitigate immunogenicity by degrading dsDNA accumulated in the cytoplasm during radiation exposure[88,89]. The classical NF-κB signaling pathway has a central role in driving radiation-induced cGAS-STING pathways. Evaluation of tumor growth after irradiation has revealed that the absence of intact classical NF-κB pathways does not have anti-tumor effects. In contrast, intact NF-κB pathways hinder tumor growth, thus underscoring the role of atypical NF-κB pathways in promoting radiation-induced anti-tumor immunity[90]. In a primary mouse model of soft tissue sarcoma, depletion of alpha-thalassemia mental retardation X-linked (Atrx), a chromatin remodeling protein and tumor suppressor, significantly intensifies radiation-induced persistent DNA damage, telomere dysfunction, and mitotic catastrophe. Remarkably, this process coincides with a pronounced impairment in the cGAS-STING-interferon signaling pathway[91].

Effects of chemotherapy on cGAS-STING pathway activation

Chemotherapy uses various agents, such as cisplatin, paclitaxel, and 5-fluorouracil, to disrupt DNA replication or induce double-strand break repair processes, thus resulting in cGAS-STING pathway activation. This activation stems from the cytoplasmic accumulation of DNA fragments, and leads to chemokine secretion, antigen presentation, and initiation of IFN-α/β signaling[21]. For example, cisplatin and gemcitabine induce the STING-dependent interferon pathway in nasopharyngeal carcinoma, and subsequently enhance MHC-I expression and IL-1β production[92]. In bladder cancer, cisplatin-induced cGAS-STING signaling not only inhibits cancer cell proliferation, but also promotes CD8$^+$ T cell and DC infiltration[93]. Microtubule-targeting agents such as paclitaxel induce pro-inflammatory responses *via* cGAS-STING, activate interferon signaling, and trigger downstream immune responses[94]. Topoisomerase inhibitors, including etoposide

and amsacrine, activate the cGAS-STING pathway by disrupting DNA replication and inducing double-strand breaks. Etoposide induces NF-κB and STING-dependent IFN-α/β signaling, thereby enhancing anti-tumor T cell responses[95]. However, amsacrine-induced DNA damage in a hypoxic environment exhibits differential effects in estrogen/progesterone receptor-positive and triple-negative breast cancer cells. These findings highlight the complex interplay of chemotherapy with the cGAS-STING pathway[96]. Additionally, ATM kinase, a regulator of DNA damage responses, plays a major role in cGAS-STING activation, and ATM inhibitors have shown potential in enhancing cancer cell sensitivity to radiation and promoting interferon responses *via* the cGAS-STING/TBK1 pathway[30,97].

In summary, these findings collectively underscore the critical role of the cGAS-STING pathway in the context of radiation and chemotherapy for cancer treatment.

Exploiting targeted therapies to activate the cGAS-STING pathway for antitumor responses

Loss of BRCA1 leads to transcriptional reprogramming in cancer cells, and intrinsic inflammation involving STING and IFN-α/β[51]. PARP1 mediates DNA repair through homologous recombination, and PARPi enhance genomic instability, thus leading to specific autologous DNA cytoplasmic leakage in cancer cells with homologous recombination defects associated with BRCA1/2 mutations; subsequently, immune infiltration increases, and tumor clearance is promoted[98]. PARPi modulate the TME by activating the cGAS-STING pathway and altering the balance of immune-stimulating signals. Low-dose CAR-T cell therapy therefore induces effective tumor regression[99], and blocking immune checkpoints further enhances the effect of PARPi[100]. Clinically, the PARPi olaparib and rucaparib exhibit properties of cell-autonomous immune modulation in ERCC1-deficient non-small cell lung cancer and BRCA1-deficient TNBC cells: they generate cytoplasmic chromatin fragments with micronuclear characteristics, and activate cGAS/STING, downstream IFN-α/β signaling, and CCL5 secretion[101]. Recent research has reported that the high-affinity PARP inhibitor thioparib targets multiple PARPs, including PARP1, PARP2, and PARP7, and displays high anti-tumor activity *in vitro* and *in vivo* in cells that bear homologous recombination defects, and are either sensitive or resistant to PARPi. Thioparib-induced STING/TBK1-dependent signal transducer and activator of transcription 1 (STAT1) phosphorylation targets PARP7, induces a robust IFN-α/β response, and slows tumor growth in immunocompetent

mouse models[102]. Olaparib in combination with the WEE1 inhibitor adavosertib triggers anti-tumor immune responses, including the STING pathway. When used in conjunction with STING agonists, this therapy further enhances persistent tumor regression in BRCA1/2 wild-type TNBC mouse tumor models and significantly improves survival outcomes[103].

Monopolar spindle 1 (MPS1) is a critical component of the spindle assembly checkpoint. In the presence of MPS1 inhibitors, cancer cells continue to divide, thus resulting in abnormal spindle formation and the appearance of numerous chromatin bridges and micronuclei, which are potent activators of the cGAS/STING pathway[104]. Kitajima et al.[105] have found that KRAS-LKB1 mutant lung cancer cells minimize the intracellular accumulation of 2′3′-cGAMP; consequently, downstream STING and STAT1 activation is avoided. However, inhibiting MPS1 effectively re-engages the STING pathway through micronucleus generation, thus effectively restoring T cell infiltration, enhancing anti-PD-1 efficacy, and producing lasting responses.

The checkpoint kinase 1 (CHK1) inhibitor prexasertib induces DNA damage in cancer cells and activates the STING/TBK1/IRF3 innate immune pathway[106], thereby increasing levels of chemokines such as CXCL10 and CCL5, and inducing activation of cytotoxic T lymphocytes[107]. Another study has reported that CHK1 inhibition increases TBK1 phosphorylation but not IRF3 phosphorylation, and does not induce IRF or NF-κB reporter gene activation[108]. In a phase II trial on recurrent ovarian cancer, treatment with prexasertib has been found to upregulate activation markers of the STING pathway such as TBK1, which correlates with prolonged progression-free survival (9 months *vs.* 3 months, $P = 0.003$)[109].

In summary, these studies have suggested that PARP, MPS1, and CHK1 inhibitors promote anti-tumor effects by activating the cGAS-STING pathway.

Harnessing epigenetic modifiers to activate the cGAS-STING signaling pathway

Epigenetic modifications such as DNA methylation and histone modifications regulate gene expression states and cellular functions. Because of the frequent epigenetic silencing of cGAS and STING genes in their promoters, alleviating this inhibition makes cells more sensitive to synthetic STING agonists and DNA-damaging agents[110]. A close correlation has been observed between cGAS-STING signaling and methylation changes, particularly those involving histone lysine demethylase 5 (KDM5)[111]. Inhibitors of KDM5 activate STING expression

in mouse colorectal cancer cells and inhibit tumor growth in a STING-dependent manner[112]. Falahat et al.[113], through whole-genome DNA methylation analysis, have discovered that hypermethylation of the promoter regions of cGAS and STING genes mediates their co-transcriptional silencing, thereby leading to widespread impairment of STING signaling in melanoma cells. DNA methyltransferase inhibitors reverse this inhibition and restore STING activity. Furthermore, in STING-defective melanoma cells, demethylation-mediated restoration of STING signaling enhances antigenicity by upregulating MHC class I molecules, and consequently mediates resistance to TIL-based immunotherapies[113]. In endometrial cancer, histone deacetylase HDAC3 interacts with β-estradiol-ERα and induces histone 3 lysine 4 deacetylation at the STING promoter, thus decreasing STING expression. Inhibiting HDAC3 increases STING expression and suppresses tumorigenesis[114]. A recent study has reported that protein arginine methyltransferase PRMT1 methylates cGAS at a conserved R133 residue, prevents cGAS dimerization, and inhibits cGAS/STING signaling in cancer cells. Inhibitors of PRMT1 activate cGAS/STING-dependent DNA sensing signals, and enhance the transcription of type I and type II interferon response genes[115]. In TP53-mutated acute myeloid leukemia (AML), the combined effects of histone modification and polyploidy trigger cGAS-STING pathway activation, lead to the secretion of cytokines and chemokines, and prompt the activation of T cells and macrophages under coculture with AML cells[116].

In addition to reactivating cGAS-STING, epigenetic modifications activate dsDNA and dsRNA sensing pathways. For instance, m⁶A methylation affects the secondary structure of DNA and alters the immunogenicity of cytoplasmic DNA. The response to m⁶A-methylated DNA is dependent on the cGAS-STING signaling axis, but is independent of MyD88/TRIF and interferon-beta promoter stimulator-1 (IPS-1) signaling[117]. Single or combined treatment with the small molecule inhibitors UNC1999 (EZH2 inhibitor) and UNC0642 (G9a inhibitor) leads to dual inhibition of H3K9me2 and H3K27me3, thus suppressing the formation of cytoplasmic chromatin fragments and consequently inhibiting the cGAS-STING pathway[118]. Chen et al.[119] have reported that glucose, a co-factor binding methyltransferase NSUN2, promotes NSUN2 oligomerization and activation, and maintains overall m⁵C RNA methylation, including TREX2. This stabilization of TREX2 limits cytoplasmic dsDNA accumulation and cGAS/STING activation, and consequently promotes tumorigenesis and resistance to anti-PD-L1 immunotherapy. Therefore,

similarly to DNA-damaging agents, epigenetic inhibitor therapy may transition cancer cells from an immunosuppressive state to an active state while concurrently activating the cGAS-STING signaling pathway.

Therapeutic strategies for STING pathway activation independent of cGAS

The activation of STING does not rely solely on the presence of cGAS. Most STING agonists have been shown to directly activate STING signaling independently of cGAS. These agonists are synthesized as prototypes of natural ligands called CDNs, similar to the binding of cGAMP to STING. However, natural CDN agonists have drawbacks limiting their application, including poor cell targeting, low stability, and inefficient transport. Additionally, genetic variations in STING alleles affect the sensing and response to exogenous and endogenous CDNs[120]. Therefore, interest is growing in CDN-based STING synthetic agonists, to enhance their stability and therapeutic efficacy.

Unleashing the power of CDN agonists in antitumor immunity

CDNs are natural agonists of the STING pathway that activate the cGAS-STING pathway in the innate immune system. Various CDN molecules, such as cGAMP, c-diGMP, and c-diAMP, play crucial roles in regulating immune responses and suppressing tumor proliferation. cGAMP activates the cGAS-STING-IRF3 pathway in animal models, reshapes the tumor immune environment, and prevents tumor metastasis by reversing epithelial-mesenchymal transition and inhibiting the PI3K/AKT pathway[121]. Administration of cGAMP triggers the activation of STING and the production of IFN-β in bone marrow cells and B cells[67]. cGAMP also enhances the anti-tumor activity of 5-FU while significantly decreasing its toxicity[122]. Several studies have indicated that depleting extracellular cGAMP decreases the infiltration of tumor-associated immune cells and eliminates the effectiveness of radiation therapy. The extracellular hydrolase ENPP1 has a role in clearing cGAMP, and the use of ENPP1 inhibitors enhances the synergistic effect of extracellular cGAMP with radiation, thus delaying tumor growth[123,124].

c-di-GMP targets MDSCs and cancer cells. Low-dose c-di-GMP increases MDSC production of IL12, whereas high doses of c-di-GMP (0.3-3 mmol/L) directly kill cancer cells, partly by activating thioredoxin-3[75]. c-di-GMP also enhances the immunogenicity and anti-tumor effects of peptide vaccines against murine B16 melanoma[125]. Another CDN, c-di-AMP, binds STING and activates downstream IFN pathways in STING-positive metastatic breast cancer cells, thus inducing the translocation of IRF-3 to mitochondria, initiating caspase-9-mediated cell death, and inhibiting clonogenicity of TNBC cells[126]. Additionally, c-di-AMP induces high levels of antigen-specific IgG antibodies and elicits potent CTL, Th1, and IFN-γ-producing CD8+ memory T cell responses[127].

To increase the stability and delivery efficiency of CDNs, researchers have designed various carriers. Intratumoral injection of virus-like particles containing cGAMP (cGAMP-VLPs) induces the differentiation of circulating tumor-specific T cells and decreases regulatory T cells (Tregs), thereby resulting in complete and sustained tumor eradication in the absence of Treg depletion[128]. Thiolated and Mn^{2+}-coordinated cGAMP nanovaccines (Mn-cGAMP NVs) enable direct cytoplasmic co-delivery of cGAMP and Mn^{2+}, and enhance the anti-tumor immune response[129]. Compared with standalone STING agonists, an exosome-delivered STING agonist, the cyclic GMP-AMP (iExoSTINGa) system, exhibits superior uptake by DCs, and leads to the accumulation of activated CD8+ T cells and enhanced anti-tumor immune responses[130]. STING activation nanoparticles (STING-NPs) developed by Shae et al.[131] have been found to enhance cytoplasmic delivery of the endogenous CDN ligand cGAMP, and to amplify STING signaling in the TME and sentinel lymph nodes. Moreover, STING-NPs have been found to increase the half-life of cGAMP by 40-fold, thus facilitating accumulation in tumors. In a B16-F10 melanoma model, STING-NPs have been found to increase the response rate to PD-L1 antibodies and to significantly improve median survival[132]. Dosta et al.[133] have recently designed poly(β-amino ester)-based nanoparticles (NPs) covalently associated with CDNs, which enable the release of STING agonists after reaching target immune cells. When absorbed by target immune cells in the TME and secondary lymphoid organs, CDN-NPs confer long-term immunity against future tumors. Moreover, the KL-7 peptide, derived from Aβ amyloid precursor fiber, self-assembles into nanotubes (PNTs) for loading and delivering c-di-GMP; the effectiveness of this therapy is significantly enhanced by stimulating the secretion of IL-6 and INF-β, along with phosphorylation of STING (S365) protein, upregulating CD4 and CD8 cytotoxic T cell killing of tumors, and enhancing the immune response in tumor tissues[134]. Additionally, DC-targeting STING agonist delivery systems have been designed. For example, the PLGA/STING@EPBM nanovaccine significantly enhances antigen cross-presentation of Clec9a+ DCs[135], and a CD103+ DC targeted CDN

formulation generates strong immune stimulation, even in relatively "cold" tumors during systemic administration[136].

In comparison to natural CDNs, CDN-based synthetic STING agonists have enhanced stability and therapeutic efficacy. ADU-S100, a modified CDN substance that has entered clinical trials, activates the STING pathway *in vitro* and *in vivo*, and displays good stability and lipophilicity in various animal models. When injected into tumors, ADU-S100 activates potent CD8+ T cell responses, and induces the production of inflammatory cytokines and chemokines[137,138]. In a phase I clinical trial (NCT02675439), ADU-S100 has demonstrated good tolerance in patients with late-stage solid tumors and lymphoma, but the overall response rate for single tumor injections was lower than expected. Furthermore, whether the concentration of ADU-S100 delivered locally was equivalent to the concentration required for activity in preclinical models is unclear[139]. Additionally, carriers for systemic delivery of ADU-S100, such as DOTAP/cholesterol liposomes[140], functionalized porphyrin-based nanoparticles (NP-AS)[141], and biodegradable ADU-S100-loaded implants[142], have shown promising preclinical efficacy.

Beyond ADU-S100, Ager et al.[143] have reported 2 highly efficient STING agonists, IACS-8803 and IACS-8779, which have demonstrated potent activation of the STING pathway *in vitro* and superior systemic anti-tumor responses in a melanoma mouse model. STING agonist 15a, a synthetic CDN structurally distinct from natural ligands, with optimized properties for intravenous administration, has potent anti-tumor efficacy through cytokine secretion and activation of CD8+ cytotoxic T cells' adaptive immune response[144]. MK-1454, a CDN synthesized by using bacterial cell lysates overexpressing cyclic GMP-AMP synthase[145], shows potent upregulation of tumor cell cytokines and effective anti-tumor activity[146]. BI 7446 (CDN 13) activates all 5 STING variants in cell assays and induces long-term, immune-mediated tumor rejection in mice[147].

In conclusion, CDN agonists, as key factors in STING pathway activation, have notable potential in anti-tumor therapy. With continued optimization of their performance and delivery modes, CDNs are expected to play greater roles in clinical applications.

Beyond CDNs: exploring novel STING agonists for cancer therapies

Non-CDN STING agonists are also gaining attention in cancer research. Ramanjulu et al.[148] have identified the dimeric aminobenzimidazole diABZI, which, through high-throughput screening, has been found to enhance STING binding. DiABZI has robust anti-tumor effects and elicits complete tumor regression in mouse models, particularly when administered intravenously, thus providing a treatment option for more patients with cancer. Compared with ADU-S100, a novel small molecule agonist, SHR1032 displays high activity in human cells of different STING genotypes, and induces IFN-β production and strong anti-tumor effects[149]. The small molecule compound 6-bromo-N-(naphthalen-1-yl)benzo[d][1,3]dioxole-5-carboxamide induces proinflammatory cytokine responses in a manner dependent on STING, and consequently regulates the activation of CD4+ and CD8+ lymphocytes[150]. The multivalent STING agonist PC7A bind a non-competitive STING surface site different from the cGAMP binding pocket, and subsequently induces tumor responses dependent on STING expression and CD8+ T cell activity[151]. The flavonoid-based compound vadimezan (DMXAA) interacts with STING and produces anti-tumor effects in various mouse models[152]. For instance, a single intratumoral injection of DMXAA results in sustained cure in as many as 60% of mice carrying undifferentiated pleomorphic sarcoma; moreover, immune phenotyping has indicated enriched lymphocyte responses in tumors at multiple time points after treatment[153]. Despite significant results in preclinical and phase I/II clinical trials, DMXAA failed in phase III clinical trials, because of its strong affinity for mSTING and lack of affinity for hSTING[152]. Other potential STING agonists include HB3089[154], ganciclovir[155], and a series of 1H-pyrrole-3-carbonitrile derivatives[156].

In summary, non-CDN STING agonists are gaining attention in cancer research. They offer new opportunities for anti-tumor therapies, particularly for patients who may not respond to CDN-based agonists. As research in this area continues, these novel STING agonists hold promise in the development of more effective cancer treatments.

Combination treatments with cGAS-STING pathway targeting and ICIs

The synergistic approach of targeting the cGAS-STING pathway in combination with ICI treatment has intriguing possibilities in cancer therapy. Notably, patients treated with paclitaxel and ICIs demonstrate a significant correlation between elevated baseline cGAS expression and positive treatment responses[157]. Cisplatin, *via* a DNA damage-mediated cGAS-STING mechanism, synergizes with PD-1 antibodies, and consequently enhances T cell infiltration and cytokine

secretion[158]. The inhibitory receptor mucin-containing molecule 3 (TIM-3), known for regulating extracellular DNA engulfment, influences chemokine expression, whereas depletion of cGAS and STING compromises this process, diminishing synergistic cytotoxicity with TIM-3 blockade[159]. Recent studies have highlighted the superiority of carbon ion irradiation (CIRT) to X-ray irradiation in inducing DNA damage and cGAS-STING activation. CIRT not only fosters immune cell infiltration but also amplifies immune checkpoint molecule expression, and slows melanoma growth when combined with PD-L1 inhibitors[160]. PRMT1 inhibitors activate cGAS/STING-dependent DNA sensing signals, in synergy with anti-PD-1 antibodies[120]. Zebularine, a demethylating agent, sensitizes the cGAS-STING pathway to DNA stimulation, in synergy with cGAMP and immune checkpoint blockade therapy, thus promoting immune cell infiltration[161]. Combined treatment with cGAMP and anti-CD47 monoclonal antibodies induces a systemic anti-tumor immune response *via* STING-IFN signaling and effectively inhibits tumor growth[162]. In a phase Ib multi-center study, the combination of ADU-S100 and the anti-PD-1 antibody spartalizumab has shown good safety profiles and high tolerance, with an overall efficacy rate greater than that of ADU-S100 monotherapy; this treatment therefore has promise for patients with late-stage solid tumors and lymphoma[163].

Limitations of treatment strategies based on activating the cGAS-STING signaling pathway

The cGAS-STING signaling pathway is a crucial component of the immune system, and its activation induces robust anti-pathogen and anti-tumor immune responses. However, recent research has revealed a series of challenges and limitations in clinical trials, despite the promising potential of CDNs in preclinical studies, thus significantly affecting their widespread application and effective treatment of tumors.

First, whereas STING agonists have shown encouraging anti-tumor immune potential in preclinical studies, emerging evidence suggests that STING activation may have opposing effects in regulating anti-tumor immunity. The dual role of the cGAS-STING pathway is context dependent and intricately associated with the evolving TME. Its effects vary depending on factors such as hypoxia, nutrient availability, and the presence of immune and stromal cells. In some cases, sustained STING activation leads to an immunosuppressive TME,

including the recruitment of MDSCs and Tregs[78,164], impaired T cell proliferation, and diminished memory cell numbers[165]. The STING-IL-35 axis in B cells weakens NK cell proliferation and diminishes NK-driven anti-tumor responses[72]. Additionally, the release of cytosolic oxidized mtDNA in oral cancer induces IFN signaling *via* the cGAS-STING-TBK1 pathway, thus upregulating the expression of PD-L1 and indoleamine 2,3-dioxygenase 1, and inhibiting T cell activation[166]. In TNBC cells, STING-mediated NF-κB induces IL-6 expression and activates pSTAT3, thereby enhancing cell survival rates and PD-L1 expression[167]. Therefore, the bidirectional effects of the cGAS-STING pathway in cancer emphasize the need for a nuanced understanding of its regulation and function in different tumor contexts. Further research on the specific molecular mechanisms underlying this duality will be essential for unlocking the full therapeutic potential of cGAS-STING modulation in cancer treatment.

The use of STING agonists is also hampered by the non-specificity of drugs. Currently, almost all available STING agonists lack tumor specificity and may potentially activate STING non-specifically throughout the body, thus leading to "on-target off-tumor" toxicity; moreover, intravenous or intraperitoneal administration of STING agonists may trigger cytokine storms[168]. Therefore, identifying STING agonists specific to tumor tissues and optimizing dosages and timing to avoid excessive STING pathway activation will be essential to avoid worsening clinical outcomes. For example, positron emission tomography imaging of ^{18}F-labeled STING agonists based on non-nucleotide MSA-2 has indicated improved affinity and specificity[169]. STING agonists conjugated with antibodies can be specifically delivered to sites expressing tumor-specific antigens[170]. Furthermore, Ding et al.[171] have designed and synthesized a photo-caged STING agonist 2 with a tumor cell-targeting carbonic anhydrase inhibitor warhead, which is readily uncaged by blue light and releases the active STING agonist, thereby significantly activating the STING signal. These efforts have provided valuable insights for developing more tumor-specific drugs.

The adverse effects of STING agonists also limit their application. DNA-damaging agents such as radiation and anthracycline chemotherapy induce delayed cardiac inflammation, owing to the activation of the cGAS-STING-IFN-α/β signaling pathway after treatment[172]. In platinum-induced cardiac toxicity research, the STING-TNF-α-AP-1 axis triggers cardiomyocyte apoptosis[173]. In mice, genetic disruption of the cGAS-STING pathway inhibits DNA damage-induced cardiac

inflammation, rescues late-stage cardiac function decline, and prevents cardiac events leading to death[172]. The STING pathway activated by mitochondrial stress and DNA leakage may lead to downstream neuroinflammation (such as neuro-degenerative brain diseases)[174]. To alleviate the adverse effects of STING agonists, researchers have explored various administration routes and methods. For instance, Chen et al.[175] have designed a small batch of esterase-activatable prodrugs based on the non-nucleotide STING agonist MSA-2, which stably binds liposome vesicles for intravenous administration. SAProsome liposomes improve delivery to the desired tumor and lymphatic compartments without causing significant systemic toxicity.

A recent study has highlighted the limitations of STING agonist treatment strategies. Li et al.[176], using a novel single-cell RNA sequencing data analysis technique called ContactTracing, have confirmed that chronic activation of the STING pathway induced by chromosomal instability promotes downstream changes in cell signaling, which suppress effective anti-tumor immunity and facilitate cancer metastasis. This finding may explain why STING agonists have shown limited efficacy in clinical trials in patients with late-stage cancer. Additionally, compared with STING agonist development, the development of STING inhibitors remains in its infancy, and nodiate drugs are just entering clinical studies. Whether targeting STING inhibitors alone elicits sufficient therapeutic effects on tumors remains unclear, and the toxicity of these inhibitors is unknown; therefore, additional research is urgently needed[177].

In summary, despite the potential of the cGAS-STING signaling pathway in anti-tumor immunity, CDNs face several challenges and limitations in clinical applications. In-depth research on the mechanisms of the cGAS-STING signaling in different types and stages of tumors, the development of tumor-specific STING agonists, and the establishment of effective biomarkers for patient selection is needed to overcome immunoresistance and activate immunogenic cell death pathways in cancer cells, thereby enabling the development of more effective treatment strategies.

Acknowledgments

Grant support

Conflict of interest statement

No potential conflicts of interest are disclosed.

Author contributions

Conceived and designed the review: Ping Wang, Lan Fang.
Collected the data: Jiawen Zhang, Sihui Yu, Lan Fang, Qiao Peng.
Figure preparation: Jiawen Zhang, Sihui Yu.
Wrote the paper: Jiawen Zhang, Sihui Yu.

References

1. Rothlin CV, Ghosh S. Lifting the innate immune barriers to antitumor immunity. J Immunother Cancer. 2020; 8: e000695.
2. Woo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol. 2015; 33: 445-74.
3. Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 2020; 10: 26-39.
4. Samson N, Ablasser A. The cGAS-STING pathway and cancer. Nat Cancer. 2022; 3: 1452-63.
5. Chen C, Xu P. Cellular functions of cGAS-STING signaling. Trends Cell Biol. 2023; 33: 630-48.
6. Vasiyani H, Wadhwa B, Singh R. Regulation of cGAS-STING signalling in cancer: approach for combination therapy. Biochim Biophys Acta Rev Cancer. 2023; 1878: 188896.
7. Pan X, Zhang W, Guo H, Wang L, Wu H, Ding L, et al. Strategies involving STING pathway activation for cancer immunotherapy: mechanism and agonists. Biochem Pharmacol. 2023; 213: 115596.
8. Zhang X, Bai XC, Chen ZJ. Structures and mechanisms in the cGAS-STING innate immunity pathway. Immunity. 2020; 53: 43-53.
9. Patel DJ, Yu Y, Xie W. cGAMP-activated cGAS-STING signaling: its bacterial origins and evolutionary adaptation by metazoans. Nat Struct Mol Biol. 2023; 30: 245-60.

10. Du M, Chen ZJ. DNA-induced liquid phase condensation of cGAS activates innate immune signaling. Science. 2018; 361: 704-9.

11. Chen S, Rong M, Lv Y, Zhu D, Xiang Y. Regulation of cGAS activity by RNA-modulated phase separation. EMBO Rep. 2023; 24: e51800.

12. Hopfner KP, Hornung V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat Rev Mol Cell Biol. 2020; 21: 501-21.

13. Gui X, Yang H, Li T, Tan X, Shi P, Li M, et al. Autophagy induction via STING trafficking is a primordial function of the cGAS pathway. Nature. 2019; 567: 262-6.

14. Zhang C, Shang G, Gui X, Zhang X, Bai XC, Chen ZJ. Structural basis of STING binding with and phosphorylation by TBK1. Nature. 2019; 567: 394-8.

15. Zhu Z, Zhou X, Du H, Cloer EW, Zhang J, Mei L, et al. STING suppresses mitochondrial VDAC2 to govern RCC growth independent of innate immunity. Adv Sci (Weinh). 2023; 10: e2203718.

16. Yum S, Li M, Fang Y, Chen ZJ. TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections. Proc Natl Acad Sci U S A. 2021; 118: e2100225118.

17. Liu B, Carlson RJ, Pires IS, Gentili M, Feng E, Hellier Q, et al. Human STING is a proton channel. Science. 2023; 381: 508-14.

18. Zhang L, Jiang C, Zhong Y, Sun K, Jing H, Song J, et al. STING is a cell-intrinsic metabolic checkpoint restricting aerobic glycolysis by targeting HK2. Nat Cell Biol. 2023; 25: 1208-22.

19. Chen Y, Wang L, Jin J, Luan Y, Chen C, Li Y, et al. p38 inhibition provides anti-DNA virus immunity by regulation of USP21 phosphorylation and STING activation. J Exp Med. 2017; 214: 991-1010.

20. Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct Target Ther. 2020; 5: 11.

21. Zhang J, Chen Y, Chen X, Zhang W, Zhao L, Weng L, et al. Deubiquitinase USP35 restrains STING-mediated interferon signaling in ovarian cancer. Cell Death Differ. 2021; 28: 139-55.

22. Yu Y, Liu J, Liu C, Liu R, Liu L, Yu Z, et al. Post-translational modifications of cGAS-STING: a critical switch for immune regulation. Cells. 2022; 11: 3043.

23. Kang J, Wu J, Liu Q, Wu X, Zhao Y, Ren J. Post-translational modifications of STING: a potential therapeutic target. Front Immunol. 2022; 13: 888147.

24. Wu Q, Leng X, Xu P. Intercellular transmission of cGAS-STING signaling in cancer. Cancer Biol Med. 2023; 20: 93-7.

25. Li Q, Qian W, Zhang Y, Hu L, Chen S, Xia Y. A new wave of innovations within the DNA damage response. Signal Transduct Target Ther. 2023; 8: 338.

26. Kornepati AVR, Rogers CM, Sung P, Curiel TJ. The complementarity of DDR, nucleic acids and anti-tumour immunity. Nature. 2023; 619: 475-86.

27. Xu Y, Chen C, Liao Z, Xu P. cGAS-STING signaling in cell death: mechanisms of action and implications in pathologies. Eur J Immunol. 2023; 53: e2350386.

28. Guan J, Lu C, Jin Q, Lu H, Chen X, Tian L, et al. MLH1 deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS-STING pathway. Cancer Cell. 2021; 39: 109-21.e5.

29. Li Y, Gao Y, Jiang X, Cheng Y, Zhang J, Xu L, et al. SAMHD1 silencing cooperates with radiotherapy to enhance anti-tumor immunity through IFI16-STING pathway in lung adenocarcinoma. J Transl Med. 2022; 20: 628.

30. Hu M, Zhou M, Bao X, Pan D, Jiao M, Liu X, et al. ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation. J Clin Invest. 2021; 131: e139333.

31. Wang Y, Wang M, Djekidel MN, Chen H, Liu D, Alt FW, et al. eccDNAs are apoptotic products with high innate immunostimulatory activity. Nature. 2021; 599: 308-14.

32. Mackenzie KJ, Carroll P, Martin CA, Murina O, Fluteau A, Simpson DJ, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017; 548: 461-5.

33. Yamazaki T, Kirchmair A, Sato A, Buqué A, Rybstein M, Petroni G, et al. Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy. Nat Immunol. 2020; 21: 1160-71.

34. Gratia M, Rodero MP, Conrad C, Bou Samra E, Maurin M, Rice GI, et al. Bloom syndrome protein restrains innate immune sensing of micronuclei by cGAS. J Exp Med. 2019; 216: 1199-213.

35. Liu H, Zhang H, Wu X, Ma D, Wu J, Wang L, et al. Nuclear cGAS suppresses DNA repair and promotes tumorigenesis. Nature. 2018; 563: 131-6.

36. Du H, Xiao N, Zhang S, Zhou X, Zhang Y, Lu Z, et al. Suppression of TREX1 deficiency-induced cellular senescence and interferonopathies by inhibition of DNA damage response. iScience. 2023; 26: 107090.

37. Ghosh M, Saha S, Li J, Montrose DC, Martinez LA. p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppression. Mol Cell. 2023; 83: 266-80.e6.

38. Fang L, Hao Y, Yu H, Gu X, Peng Q, Zhuo H, et al. Methionine restriction promotes cGAS activation and chromatin untethering through demethylation to enhance antitumor immunity. Cancer Cell. 2023; 41: 1118-33.e12.

39. Fukuda S, Narendran S, Varshney A, Nagasaka Y, Wang SB, Ambati K, et al. Alu complementary DNA is enriched in atrophic macular degeneration and triggers retinal pigmented epithelium toxicity via cytosolic innate immunity. Sci Adv. 2021; 7: eabj3658.

40. Mathavarajah S, Dellaire G. LINE-1: an emerging initiator of cGAS-STING signalling and inflammation that is dysregulated in disease. Biochem Cell Biol. 2023. doi: 10.1139/bcb-2023-0134.

41. Gulen MF, Samson N, Keller A, Schwabenland M, Liu C, Glück S, et al. cGAS-STING drives ageing-related inflammation and neurodegeneration. Nature. 2023; 620: 374-80.

42. Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun. 2019; 10: 5408.

43. Liu Y, Pagacz J, Wolfgeher DJ, Bromerg KD, Gorman JV, Kron SJ. Senescent cancer cell vaccines induce cytotoxic T cell responses targeting primary tumors and disseminated tumor cells. J Immunother Cancer. 2023; 11: e005862.

44. Wang H, Hu S, Chen X, Shi H, Chen C, Sun L, et al. cGAS is essential for the antitumor effect of immune checkpoint blockade. Proc Natl Acad Sci U S A. 2017; 114: 1637-42.

45. Lv M, Chen M, Zhang R, Zhang W, Wang C, Zhang Y, et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 2020; 30: 966-79.

46. Lu T, Zhang Z, Bi Z, Lan T, Zeng H, Liu Y, et al. TFAM deficiency in dendritic cells leads to mitochondrial dysfunction and enhanced antitumor immunity through cGAS-STING pathway. J Immunother Cancer. 2023; 11: e005430.

47. Cousin C, Oberkampf M, Felix T, Rosenbaum P, Weil R, Fabrega S, et al. Persistence of integrase-deficient lentiviral vectors correlates with the induction of STING-independent CD8+ T cell responses. Cell Rep. 2019; 26: 1242-57.e7.

48. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014; 41: 843-52.

49. Ohkuri T, Ghosh A, Kosaka A, Zhu J, Ikeura M, David M, et al. STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res. 2014; 2: 1199-208.

50. Ohkuri T, Kosaka A, Ishibashi K, Kumai T, Hirata Y, Ohara K, et al. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site. Cancer Immunol Immunother. 2017; 66: 705-16.

51. Bruand M, Barras D, Mina M, Ghisoni E, Morotti M, Lanitis E, et al. Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Rep. 2021; 36: 109412.

52. Liu X, Cen X, Wu R, Chen Z, Xie Y, Wang F, et al. ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockade. Nat Commun. 2023; 14: 4066.

53. Ka NL, Park MK, Kim SS, Jeon Y, Hwang S, Kim SM, et al. NR1D1 stimulates antitumor immune responses in breast cancer by activating cGAS-STING signaling. Cancer Res. 2023; 83: 3045-58.

54. Du SS, Chen GW, Yang P, Chen YX, Hu Y, Zhao QQ, et al. Radiation therapy promotes hepatocellular carcinoma immune cloaking via PD-L1 upregulation induced by cGAS-STING activation. Int J Radiat Oncol Biol Phys. 2022; 112: 1243-55.

55. Huang Y, Qin G, Cui T, Zhao C, Ren J, Qu X. A bimetallic nanoplatform for STING activation and CRISPR/Cas mediated depletion of the methionine transporter in cancer cells restores anti-tumor immune responses. Nat Commun. 2023; 14: 4647.

56. Hu J, Sánchez-Rivera FJ, Wang Z, Johnson GN, Ho YJ, Ganesh K, et al. STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature. 2023; 616: 806-13.

57. Quaney MJ, Pritzl CJ, Luera D, Newth RJ, Knudson KM, Saxena V, et al. STING controls T cell memory fitness during infection through T cell-intrinsic and IDO-dependent mechanisms. Proc Natl Acad Sci U S A. 2023; 120: e2205049120.

58. Xu T, Yu S, Zhang J, Wu S. Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers. J Hematol Oncol. 2021; 14: 181.

59. Zhou Y, Fei M, Zhang G, Liang WC, Lin W, Wu Y, et al. Blockade of the phagocytic receptor MerTK on tumor-associated macrophages enhances P2X7R-dependent STING activation by tumor-derived cGAMP. Immunity. 2020; 52: 357-73.e9.

60. Lee SJ, Yang H, Kim WR, Lee YS, Lee WS, Kong SJ, et al. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer. J Immunother Cancer. 2021; 9: e002195.

61. Zhu M, Tang X, Zhu Z, Gong Z, Tang W, Hu Y, et al. STING activation in macrophages by vanillic acid exhibits antineoplastic potential. Biochem Pharmacol. 2023; 213: 115618.

62. Liu Y, Sun Q, Zhang C, Ding M, Wang C, Zheng Q, et al. STING-IRG1 inhibits liver metastasis of colorectal cancer by regulating the polarization of tumor-associated macrophages. iScience. 2023; 26: 107376.

63. Sun Y, Hu H, Liu Z, Xu J, Gao Y, Zhan X, et al. Macrophage STING signaling promotes NK cell to suppress colorectal cancer liver metastasis via 4-1BBL/4-1BB co-stimulation. J Immunother Cancer. 2023; 11: e006481.

64. Mondal I, Das O, Sun R, Gao J, Yu B, Diaz A, et al. PP2Ac deficiency enhances tumor immunogenicity by activating STING-Type I interferon signaling in Glioblastoma. Cancer Res. 2023; 83: 2527-42.

65. Ho WS, Mondal I, Xu B, Das O, Sun R, Chiou P, et al. PP2Ac/STRN4 negatively regulates STING-type I IFN signaling in tumor-associated macrophages. J Clin Invest. 2023; 133: e162139.

66. Wang Q, Bergholz JS, Ding L, Lin Z, Kabraji SK, Hughes ME, et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat Commun. 2022; 13: 3022.

67. Marcus A, Mao AJ, Lensink-Vasan M, Wang L, Vance RE, Raulet DH. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity. 2018; 49: 754-63.e4.

68. Nicolai CJ, Wolf N, Chang IC, Kirn G, Marcus A, Ndubaku CO, et al. NK cells mediate clearance of CD8+ T cell-resistant tumors in response to STING agonists. Sci Immunol. 2020; 5: eaaz2738.

69. Knelson EH, Ivanova EV, Tarannum M, Campisi M, Lizotte PH, Booker MA, et al. Activation of Tumor-Cell STING Primes NK-Cell Therapy. Cancer Immunol Res. 2022; 10: 947-61.

70. Lu S, Concha-Benavente F, Shayan G, Srivastava RM, Gibson SP, Wang L, et al. STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV+ status in head and neck cancer. Oral Oncol. 2018; 78: 186-93.

71. Da Y, Liu Y, Hu Y, Liu W, Ma J, Lu N, et al. STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer. Oncoimmunology. 2022; 11: 2054105.

72. Li S, Mirlekar B, Johnson BM, Brickey WJ, Wrobel JA, Yang N, et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature. 2022; 610: 373-80.

73. Lu L, Yang C, Zhou X, Wu L, Hong X, Li W, et al. STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1+ NK cells. Cell Rep. 2023; 42: 113108.

74. Kho VM, Mekers VE, Span PN, Bussink J, Adema GJ. Radiotherapy and cGAS/STING signaling: impact on MDSCs in the tumor microenvironment. Cell Immunol. 2021; 362: 104298.

75. Chandra D, Quispe-Tintaya W, Jahangir A, Asafu-Adjei D, Ramos I, Sintim HO, et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol Res. 2014; 2: 901-10.

76. Zhang CX, Ye SB, Ni JJ, Cai TT, Liu YN, Huang DJ, et al. STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion. Cell Death Differ. 2019; 26: 2314-28.

77. Liang H, Deng L, Hou Y, Meng X, Huang X, Rao E, et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat Commun. 2017; 8: 1736.

78. Nambiar DK, Viswanathan V, Cao H, Zhang W, Guan L, Chamoli M, et al. Galectin-1 mediates chronic STING activation in tumors to promote metastasis through MDSC recruitment. Cancer Res. 2023; 83: 3205-19.

79. Kabashima A, Matsuo Y, Ito S, Akiyama Y, Ishii T, Shimada S, et al. cGAS-STING signaling encourages immune cell overcoming of fibroblast barricades in pancreatic cancer. Sci Rep. 2022; 12: 10466.

80. Ma Z, Li X, Mao Y, Wei C, Huang Z, Li G, et al. Interferon-dependent SLC14A1+ cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. Cancer Cell. 2022; 40: 1550-65.e7.

81. Dora D, Rivard C, Yu H, Pickard SL, Laszlo V, Harko T, et al. Protein expression of immune checkpoints STING and MHCII in small cell lung cancer. Cancer Immunol Immunother. 2023; 72: 561-78.

82. Arwert EN, Milford EL, Rullan A, Derzsi S, Hooper S, Kato T, et al. STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy. Nat Cell Biol. 2020; 22: 758-66.

83. Mekers VE, Kho VM, Ansems M, Adema GJ. cGAS/cGAMP/STING signal propagation in the tumor microenvironment: key role for myeloid cells in antitumor immunity. Radiother Oncol. 2022; 174: 158-67.

84. He Y, Yang Y, Huang W, Yang S, Xue X, Zhu K, et al. Manganese facilitated cGAS-STING-IFNI pathway activation induced by ionizing radiation in glioma cells. Int J Radiat Biol. 2023; 99: 1890-907.

85. White MJ, McArthur K, Metcalf D, Lane RM, Cambier JC, Herold MJ, et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell. 2014; 159: 1549-62.

86. Friedland W, Schmitt E, Kundrát P, Baiocco G, Ottolenghi A. Track-structure simulations of energy deposition patterns to mitochondria and damage to their DNA. Int J Radiat Biol. 2019; 95: 3-11.

87. Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017; 548: 466-70.

88. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017; 8: 15618.

89. Diamond JM, Vanpouille-Box C, Spada S, Rudqvist NP, Chapman JR, Ueberheide BM, et al. Exosomes shuttle TREX1-sensitive IFN-stimulatory dsDNA from irradiated cancer cells to DCs. Cancer Immunol Res. 2018; 6: 910-20.

90. Hou Y, Liang H, Rao E, Zheng W, Huang X, Deng L, et al. Non-canonical NF-κB antagonizes STING sensor-mediated DNA sensing in radiotherapy. Immunity. 2018; 49: 490-503.e4.

91. Floyd W, Pierpoint M, Su C, Patel R, Luo L, Deland K, et al. Atrx deletion impairs CGAS/STING signaling and increases sarcoma response to radiation and oncolytic herpesvirus. J Clin Invest. 2023; 133: e149310.

92. Lv J, Wei Y, Yin JH, Chen YP, Zhou GQ, Wei C, et al. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat Med. 2023; 29: 1424-36.

93. Fu G, Wu Y, Zhao G, Chen X, Xu Z, Sun J, et al. Activation of cGAS-STING signal to inhibit the proliferation of bladder cancer: the immune effect of Cisplatin. Cells. 2022; 11: 3011.

94. Groelly FJ, Porru M, Zimmer J, Benainous H, De Visser Y, Kosova AA, et al. Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours. EMBO Mol Med. 2022; 14: e14501.

95. Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, et al. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Invest. 2019; 129: 4850-62.

96. Ka NL, Lim GY, Hwang S, Kim SS, Lee MO. IFI16 inhibits DNA repair that potentiates type-I interferon-induced antitumor effects in triple negative breast cancer. Cell Rep. 2021; 37: 110138.

97. Chiu LY, Sun Q, Zenke FT, Blaukat A, Vassilev LT. Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death. Aging (Albany NY). 2023; 15: 492-512.

98. Kim C, Wang XD, Yu Y. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response. Elife. 2020; 9: e60637.

99. Ji F, Zhang F, Zhang M, Long K, Xia M, Lu F, et al. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway. J Hematol Oncol. 2021; 14: 152.

100. Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019; 79: 311-9.

101. Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, et al. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J Clin Invest. 2019; 129: 1211-28.

102. Wang LM, Wang P, Chen XM, Yang H, Song SS, Song Z, et al. Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance. EMBO Mol Med. 2023; 15: e16235.

103. Teo ZL, O'Connor MJ, Versaci S, Clarke KA, Brown ER, Percy LW, et al. Combined PARP and WEE1 inhibition triggers anti-tumor immune response in BRCA1/2 wildtype triple-negative breast cancer. NPJ Breast Cancer. 2023; 9: 68.

104. Flynn PJ, Koch PD, Mitchison TJ. Chromatin bridges, not micronuclei, activate cGAS after drug-induced mitotic errors in human cells. Proc Natl Acad Sci U S A. 2021; 118: e2103585118.

105. Kitajima S, Tani T, Springer BF, Campisi M, Osaki T, Haratani K, et al. MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer. Cancer Cell. 2022; 40: 1128-44.e8.

106. Wayne J, Brooks T, Landras A, Massey AJ. Targeting DNA damage response pathways to activate the STING innate immune signaling pathway in human cancer cells. FEBS J. 2021; 288: 4507-40.

107. Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019; 9: 646-61.

108. Brooks T, Wayne J, Massey AJ. Checkpoint Kinase 1 (Chk1) inhibition fails to activate the Stimulator of Interferon Genes (STING) innate immune signalling in a human coculture cancer system. Mol Biomed. 2021; 2: 19.

109. Lampert EJ, Cimino-Mathews A, Lee JS, Nair J, Lee MJ, Yuno A, et al. Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses. J Immunother Cancer. 2020; 8: e000516.

110. Falahat R, Berglund A, Perez-Villarroel P, Putney RM, Hamaidi I, Kim S, et al. Epigenetic state determines the in vivo efficacy of STING agonist therapy. Nat Commun. 2023; 14: 1573.

111. Hao F. Entanglement of methylation changes and cGAS-STING signaling in non-small-cell lung cancer. Comb Chem High Throughput Screen. 2023; 26: 224-35.

112. Zheng H, Wu L, Xiao Q, Meng X, Hafiz A, Yan Q, et al. Epigenetically suppressed tumor cell intrinsic STING promotes tumor immune escape. Biomed Pharmacother. 2023; 157: 114033.

113. Falahat R, Berglund A, Putney RM, Perez-Villarroel P, Aoyama S, Pilon-Thomas S, et al. Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. Proc Natl Acad Sci U S A. 2021; 118: e2013598118.

114. Chen G, Yan Q, Liu L, Wen X, Zeng H, Yin S. Histone Deacetylase 3 governs β-Estradiol-ERα-involved endometrial tumorigenesis via inhibition of STING transcription. Cancers (Basel). 2022; 14: 4718.

115. Liu J, Bu X, Chu C, Dai X, Asara JM, Sicinski P, et al. PRMT1 mediated methylation of cGAS suppresses anti-tumor immunity. Nat Commun. 2023; 14: 2806.

116. Man CH, Lam W, Dang CC, Zeng XY, Zheng LC, Chan NN, et al. Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML. Blood. 2023; 142: 2002-15.

117. Balzarolo M, Engels S, de Jong AJ, Franke K, van den Berg TK, et al. m6A methylation potentiates cytosolic dsDNA recognition in a sequence-specific manner. Open Biol. 2021; 11: 210030.

118. Zhang N, Shang M, Li H, Wu L, Dong M, Huang B, et al. Dual inhibition of H3K9me2 and H3K27me3 promotes tumor cell senescence without triggering the secretion of SASP. Int J Mol Sci. 2022; 23: 3911.

119. Chen T, Xu ZG, Luo J, Manne RK, Wang Z, Hsu CC, et al. NSUN2 is a glucose sensor suppressing cGAS/STING to maintain tumorigenesis and immunotherapy resistance. Cell Metab. 2023; 35: 1782-98.

120. Walker MM, Kim S, Crisler WJ, Nguyen K, Lenz LL, Cambier JC, et al. Selective loss of responsiveness to exogenous but not endogenous cyclic-dinucleotides in mice expressing STING-R231H. Front Immunol. 2020; 11: 238.

121. Lu X, Wang X, Cheng H, Wang X, Liu C, Tan X. Anti-triple-negative breast cancer metastasis efficacy and molecular mechanism of the STING agonist for innate immune pathway. Ann Med. 2023; 55: 2210845.

122. Li T, Cheng H, Yuan H, Xu Q, Shu C, Zhang Y, et al. Antitumor activity of cGAMP via stimulation of cGAS-cGAMP-STING-IRF3 mediated innate immune response. Sci Rep. 2016; 6: 19049.

123. Li J, Duran MA, Dhanota N, Chatila WK, Bettigole SE, Kwon J, et al. Metastasis and immune evasion from extracellular cGAMP hydrolysis. Cancer Discov. 2021; 11: 1212-27.

124. Carozza JA, Cordova AF, Brown JA, AlSaif Y, Böhnert V, Cao X, et al. ENPP1's regulation of extracellular cGAMP is a ubiquitous mechanism of attenuating STING signaling. Proc Natl Acad Sci U S A. 2022; 119: e2119189119.

125. Wang Z, Celis E. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol Immunother. 2015; 64: 1057-66.

126. Vasiyani H, Shinde A, Roy M, Mane M, Singh K, Singh J, et al. The analog of cGAMP, c-di-AMP, activates STING mediated cell death pathway in estrogen-receptor negative breast cancer cells. Apoptosis. 2021; 26: 293-306.

127. Volckmar J, Knop L, Stegemann-Koniszewski S, Schulze K, Ebensen T, Guzmán CA, et al. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells. Vaccine. 2019; 37: 4963-74.

128. Jneid B, Bochnakian A, Hoffmann C, Delisle F, Djacoto E, Sirven P, et al. Selective STING stimulation in dendritic cells primes antitumor T cell responses. Sci Immunol. 2023; 8: eabn6612.

129. Chen C, Tong Y, Zheng Y, Shi Y, Chen Z, Li J, et al. Cytosolic delivery of thiolated Mn-cGAMP nanovaccine to enhance the antitumor immune responses. Small. 2021; 17: e2102241.

130. McAndrews KM, Che SPY, LeBleu VS, Kalluri R. Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity. J Biol Chem. 2021; 296: 100523.

131. Shae D, Becker KW, Christov P, Yun DS, Lytton-Jean AKR, Sevimli S, et al. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat Nanotechnol. 2019; 14: 269-78.

132. Wehbe M, Wang-Bishop L, Becker KW, Shae D, Baljon JJ, He X, et al. Nanoparticle delivery improves the pharmacokinetic

properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration. J Control Release. 2021; 330: 1118-29.

133. Dosta P, Cryer AM, Dion MZ, Shiraishi T, Langston SP, Lok D, et al. Investigation of the enhanced antitumour potency of STING agonist after conjugation to polymer nanoparticles. Nat Nanotechnol. 2023; 18: 1351-63.

134. Zhang Z, Liu J, Xiao M, Zhang Q, Liu Z, Liu M, et al. Peptide nanotube loaded with a STING agonist, c-di-GMP, enhance cancer immunotherapy against melanoma. Nano Res. 2023; 16: 5206-15.

135. Gou S, Liu W, Wang S, Chen G, Chen Z, Qiu L, et al. Engineered nanovaccine targeting Clec9a+ dendritic cells remarkably enhances the cancer immunotherapy effects of STING agonist. Nano Lett. 2021; 21: 9939-50.

136. Doshi AS, Cantin S, Prickett LB, Mele DA, Amiji M. Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy. J Control Release. 2022; 345: 721-33.

137. Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH, et al. Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity. Cell Rep. 2018; 25: 3074-3085.e5.

138. Vonderhaar EP, Barnekow NS, McAllister D, McOlash L, Eid MA, Riese MJ, et al. STING activated tumor-intrinsic type I interferon signaling promotes CXCR3 dependent antitumor immunity in pancreatic cancer. Cell Mol Gastroenterol Hepatol. 2021; 12: 41-58.

139. Meric-Bernstam F, Sweis RF, Hodi FS, Messersmith WA, Andtbacka RHI, Ingham M, et al. Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced/metastatic solid tumors or lymphomas. Clin Cancer Res. 20225; 28: 677-88.

140. Ji N, Wang M, Tan C. Liposomal delivery of MIW815 (ADU-S100) for potentiated STING activation. Pharmaceutics. 2023; 15: 638.

141. Ge T, Ge W, Zhang L, Yu G, Li Y, Sun L, et al. Photodynamic immunotherapy using ADU-S100-modified nanoparticles to treat triple-negative breast cancer. Nanomedicine (Lond). 2023; 18: 755-67.

142. Berger G, Knelson EH, Jimenez-Macias JL, Nowicki MO, Han S, Panagioti E, et al. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models. Proc Natl Acad Sci U S A. 2022; 119: e2111003119.

143. Ager CR, Zhang H, Wei Z, Jones P, Curran MA, Di Francesco ME. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy. Bioorg Med Chem Lett. 2019; 29: 126640.

144. Vyskocil S, Cardin D, Ciavarri J, Conlon J, Cullis C, England D, et al. Identification of novel carbocyclic pyrimidine cyclic dinucleotide STING agonists for antitumor immunotherapy using systemic intravenous route. J Med Chem. 2021; 64: 6902-23.

145. McIntosh JA, Liu Z, Andresen BM, Marzijarani NS, Moore JC, Marshall NM, et al. A kinase-cGAS cascade to synthesize a therapeutic STING activator. Nature. 2022; 603: 439-44.

146. Chang W, Altman MD, Lesburg CA, Perera SA, Piesvaux JA, Schroeder GK, et al. Discovery of MK-1454: a potent cyclic dinucleotide stimulator of interferon genes agonist for the treatment of cancer. J Med Chem. 2022; 65: 5675-89.

147. Kuttruff CA, Fleck M, Carotta S, Arnhof H, Bretschneider T, Dahmann G, et al. Discovery of BI 7446: a potent cyclic dinucleotide STING agonist with broad-spectrum variant activity for the treatment of cancer. J Med Chem. 2023; 66: 9376-400.

148. Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018; 564: 439-43.

149. Song C, Liu D, Liu S, Li D, Horecny I, Zhang X, et al. SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis. Sci Rep. 2022; 12: 8579.

150. Zhang X, Liu B, Tang L, Su Q, Hwang N, Sehgal M, et al. Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist. ACS Infect Dis. 2019; 5: 1139-49.

151. Li S, Luo M, Wang Z, Feng Q, Wilhelm J, Wang X, et al. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nat Biomed Eng. 2021; 5: 455-66.

152. Daei Farshchi Adli A, Jahanban-Esfahlan R, Seidi K, Samandari-Rad S, Zarghami N. An overview on Vadimezan (DMXAA): the vascular disrupting agent. Chem Biol Drug Des. 2018; 91: 996-1006.

153. Marritt KL, Hildebrand KM, Hildebrand KN, Singla AK, Zemp FJ, Mahoney DJ, et al. Intratumoral STING activation causes durable immunogenic tumor eradication in the KP soft tissue sarcoma model. Front Immunol. 2023; 13: 1087991.

154. Xie Z, Wang Z, Fan F, Zhou J, Hu Z, Wang Q, et al. Structural insights into a shared mechanism of human STING activation by a potent agonist and an autoimmune disease-associated mutation. Cell Discov. 2022; 8: 133.

155. Kundu N, Kumar A, Corona C, Chen Y, Seth S, Karuppagounder SS, et al. A STING agonist preconditions against ischaemic stroke via an adaptive antiviral Type 1 interferon response. Brain Commun. 2022; 4: fcac133.

156. Shen C, Xu P, Zhang C, Su Z, Shan B, Li R, et al. Structure-activity relationship study of 1H-Pyrrole-3-carbonitrile derivatives as STING receptor agonists. ACS Med Chem Lett. 2023; 14: 1079-87.

157. Hu Y, Manasrah BK, McGregor SM, Lera RF, Norman RX, Tucker JB, et al. Paclitaxel induces micronucleation and activates pro-inflammatory cGAS-STING signaling in triple-negative breast cancer. Mol Cancer Ther. 2021; 20: 2553-67.

158. Glorieux C, Xia X, You X, Wang Z, Han Y, Yang J, et al. Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer. J Adv Res. 2022; 40: 109-24.

159. de Mingo Pulido Á, Hänggi K, Celias DP, Gardner A, Li J, Batista-Bittencourt B, et al. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity. 2021; 54: 1154-67.e7.

160. Guo Y, Shen R, Wang F, Wang Y, Xia P, Wu R, et al. Carbon ion irradiation induces DNA damage in melanoma and optimizes the tumor microenvironment based on the cGAS-STING pathway. J Cancer Res Clin Oncol. 2023; 149: 6315-28.

161. Lai J, Fu Y, Tian S, Huang S, Luo X, Lin L, et al. Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice. Mol Ther. 2021; 29: 1758-71.

162. Kosaka A, Ishibashi K, Nagato T, Kitamura H, Fujiwara Y, Yasuda S, et al. CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. J Exp Med. 2021; 218: e20200792.

163. Meric-Bernstam F, Sweis RF, Kasper S, Hamid O, Bhatia S, Dummer R, et al. Combination of the STING agonist MIW815 (ADU-S100) and PD-1 inhibitor spartalizumab in advanced/metastatic solid tumors or lymphomas: an open-label, multicenter, phase Ib Study. Clin Cancer Res. 2023; 29: 110-21.

164. Liang D, Xiao-Feng H, Guan-Jun D, Er-Ling H, Sheng C, Ting-Ting W, et al. Activated STING enhances Tregs infiltration in the HPV-related carcinogenesis of tongue squamous cells via the c-jun/CCL22 signal. Biochim Biophys Acta. 2015; 1852: 2494-503.

165. Cerboni S, Jeremiah N, Gentili M, Gehrmann U, Conrad C, Stolzenberg MC, et al. Intrinsic antiproliferative activity of the innate sensor STING in T lymphocytes. J Exp Med. 2017; 214: 1769-85.

166. Cheng AN, Cheng LC, Kuo CL, Lo YK, Chou HY, Chen CH, et al. Mitochondrial Lon-induced mtDNA leakage contributes to PD-L1-mediated immunoescape via STING-IFN signaling and extracellular vesicles. J Immunother Cancer. 2020; 8: e001372.

167. Vasiyani H, Mane M, Rana K, Shinde A, Roy M, Singh J, et al. DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients. Apoptosis. 2022; 27: 961-78.

168. Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, et al. Phase I study of SYNB1891, an engineered E. coli Nissle strain expressing STING agonist, with and without Atezolizumab in advanced malignancies. Clin Cancer Res. 2023; 29: 2435-44.

169. Fang J, Feng L, Meng L, Wang X, Liu H, Huang L, et al. A novel ^{18}F-labeled agonist for PET imaging of stimulator of interferon gene expression in tumor-bearing mice. Eur J Nucl Med Mol Imaging. 2022; 50: 27-37.

170. Duvall JR, Thomas JD, Bukhalid RA, Catcott KC, Bentley KW, Collins SD, et al. Discovery and optimization of a STING agonist platform for application in antibody drug conjugates. J Med Chem. 2023; 66: 10715-33.

171. Ding C, Du M, Xiong Z, Wang X, Li H, He E, et al. Photochemically controlled activation of STING by CAIX-targeting photocaged agonists to suppress tumor cell growth. Chem Sci. 2023; 14: 5956-64.

172. Shamseddine A, Patel SH, Chavez V, Moore ZR, Adnan M, Di Bona M, et al. Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies. J Exp Med. 2023; 220: e20220809.

173. Wang L, Zhang S, Han J, Nie X, Qi Y, Han Y, et al. Activation of STING pathway contributed to Cisplatin-induced cardiac dysfunction via promoting the activation of TNF-α-AP-1 signal pathway. Front Pharmacol. 2021; 12: 711238.

174. Ferecskó AS, Smallwood MJ, Moore A, Liddle C, Newcombe J, Holley J, et al. STING-triggered CNS inflammation in human neurodegenerative diseases. Biomedicines. 2023; 11: 1375.

175. Chen X, Meng F, Xu Y, Li T, Chen X, Wang H. Chemically programmed STING-activating nano-liposomal vesicles improve anticancer immunity. Nat Commun. 2023; 14: 4584.

176. Li J, Hubisz MJ, Earlie EM, Duran MA, Hong C, Varela AA, et al. Non-cell-autonomous cancer progression from chromosomal instability. Nature. 2023; 620: 1080-8.

177. Shen A, Chen M, Chen Q, Liu Z, Zhang A. Recent advances in the development of STING inhibitors: an updated patent review. Expert Opin Ther Pat. 2022; 32: 1131-43.